CAS: 1088715-84-7; (2S,5S,8S,11R,14S,20R)-N-((S)-1-Amino-6-(Isopropylamino)-1-Oxohexan-2-yl)-2-Benzyl-11-(3-Guanidinopropyl)-5-(4-Hydroxybenzyl)-8-(4-(Isopropylamino)Butyl)-14-(Naphthalen-2-Ylmethyl)-3,6,9,12,15,18,23-Heptaoxo-1,4,7,10,13,16,19-Heptaazacyclotricosane-20-Carboxamide
- 英文名称(2S,5S,8S,11R,14S,20R)-N-((S)-1-Amino-6-(Isopropylamino)-1-Oxohexan-2-yl)-2-Benzyl-11-(3-Guanidinopropyl)-5-(4-Hydroxybenzyl)-8-(4-(Isopropylamino)Butyl)-14-(Naphthalen-2-Ylmethyl)-3,6,9,12,15,18,23-Heptaoxo-1,4,7,10,13,16,19-Heptaazacyclotricosane-20-Carboxamide
- IUPAC名称(2S,5S,8S,11R,14S,20R)-N-((S)-1-amino-6-(isopropylamino)-1-oxohexan-2-yl)-2-benzyl-11-(3-guanidinopropyl)-5-(4-hydroxybenzyl)-8-(4-(isopropylamino)butyl)-14-(naphthalen-2-ylmethyl)-3,6,9,12,15,18,23-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosane-20-carboxamide
- 其它别名Cyclo[phe-Tyr-Lys(Ipr)-D-Arg-2-Nal-Gly-D-Glu]-Lys(Ipr)-Nh2; Cyclo[phe-Tyr-Lys(Ipr)-D-Arg-2-Nal-Gly-D-Glu]-Lys(Ipr)-Nh2-2-Nal-Gly-D-Glu]-Lys(Ipr)-Nh2A; L-Lysinamide, L-Phenylalanyl-L-Tyrosyl-N6-(1-Methylethyl)-L-Lysyl-D-Arginyl-3-(2-Naphthalenyl)-L-Alanylglycyl-D-α-Glutamyl-N6-(1-Methylethyl)-, (7→1)-Lactam; (2S,5S,8S,11R,14S,20R)-N-((S)-1-Amino-6-(Isopropylamino)-1-Oxohexan-2-yl)-2-Benzyl-11-(3-Guanidinopropyl)-5-(4-Hydroxybenzyl)-8-(4-(Isopropylamino)Butyl)-14-(Naphthalen-2-Ylmethyl)-3,6,9,12,15,18,23-Heptaoxo-1,4,7,10,13,16,19-Heptaazacyclotricosane-20-Carboxamide
- CAS编号1088715-84-7
- MFCD编号:MFCD30537218
- FDA UNII编号:L53SQF2I6G
- 分子式:C62H88N14O10分子量:1189.47
- 产品CID: 124858
- 产品分类Inhibitors/Agonists → Immunology/Inflammation → CXCR
物理性质
合成工艺路线路线简述
- 合成目标产物 Cyclo[phe-Tyr-Lys(Ipr)-D-Arg-2-Nal-Gly-D-Glu]-Lys(Ipr)-Nh2 主要起始原料 Ethanamine, N-[(3,5-Dichlorophenyl)Methylene]-2,2-Diethoxy-
- (文献来源)合成步骤主要原料 Ethanamine, N-[(3,5-Dichlorophenyl)Methylene]-2,2-Diethoxy-
专利信息
专利号:US-2020354404-A1
优先权日:2019-05-09
标 题 :Peptidomimetic agents, synthesis and uses thereof
发明人：AL-ABED YOUSEF
权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
摘要:Compounds for use in synthesis of peptidomimetic agents; synthesis of peptidomimetic agents; peptidomimetic diagnostic and therapeutic agents; and uses of the compounds and peptidomimetic agents in drug discovery, diagnosis, prevention and treatment of diseases are described.
专利号:US-10919882-B2
优先权日:2019-05-09
标题:Compounds for use in synthesis of peptidomimetics
专利号:US-11414405-B2
优先权日:2019-05-09
标 题:Compounds for use in synthesis of peptidomimetics
专利号:US-2021130331-A1
优先权日:2019-05-09
标 题:Compounds for use in synthesis of peptidomimetics
专利号:CA-3174239-A1
优先权日:2020-05-08
标题:Dimers for use in synthesis of peptidomimetics
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Cho BS, Zeng Z, Mu H, Wang Z, Konoplev S, McQueen T, Protopopova M, Cortes J, Marszalek JR, Peng SB, Ma W, Davis RE, Thornton DE, Andreeff M, Konopleva M. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015 Jul 9;126(2):222-32. doi: 10.1182/blood-2015-02-628677. Epub 2015 Jun 1. Erratum in: Blood. 2015 Aug 20;126(8):1049. Konoplev, Sergej [added].
2: Peng SB, Zhang X, Paul D, Kays LM, Gough W, Stewart J, Uhlik MT, Chen Q, Hui YH, Zamek-Gliszczynski MJ, Wijsman JA, Credille KM, Yan LZ. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 2015 Feb;14(2):480-90. doi: 10.1158/1535-7163.MCT-14-0850. Epub 2014 Dec 12. doi: 10.1158/1078-0432.CCR-13-2686. Epub 2014 Apr 11. Erratum in: Clin Cancer Res. 2014 Aug 15;20(16):4414. (Last updated: 4/21/2016)
📝 需求与反馈
尽可能描述清楚需求与问题信息
